Not a good buy right now for an impatient entry: there is no Intellectia buy signal and momentum is mixed (bullish longer trend but weakening short-term momentum).
Price is only modestly above the pivot (~12.16) with nearer-term upside capped by resistance at ~13.56, while downside risk to ~10.76 exists if momentum fades.
With earnings scheduled for 2026-02-12 (after hours) and the company still loss-making, the near-term setup is not attractive for a “buy immediately” approach.
Momentum: MACD histogram is negative (-0.0512) but contracting, suggesting bearish momentum is fading, not yet reversed.
RSI: RSI_6 ~60.9 (neutral-to-slightly-bullish), not overbought, but also not a clear “buy-the-dip” reading.
Key levels: Pivot ~12.159 (current pre-market 12.49 is slightly above). Resistance: R1 ~13.557 then R2 ~14.421. Support: S1 ~10.761 then S2 ~9.897.
Pattern-based forward drift: Similar-pattern stats imply a slight negative bias next day (-1.37%) and flat next week (-0.04%), with modestly positive 1-month (+1.68%).
Positive Catalysts
was positive (+7.59% YoY).
Neutral/Negative Catalysts
Upcoming earnings (2026-02-
introduces binary/event risk for a near-term buy.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 696,995 (+7.59% YoY) — top-line growth, but from a small base.
Net income: -720,607 (down -7.71% YoY) — losses worsening.
Takeaway: growth exists, but it is not translating into improving earnings yet.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price-target change data was provided, so recent Wall Street trend cannot be confirmed.
Wall Street-style pros (based on provided data): improving revenue and still-high gross margin level.
Wall Street-style cons (based on provided data): continued net losses, declining EPS and margin, and no clear catalyst/coverage signals shown.
Influential/political activity: no recent congress trading data available; hedge funds and insiders shown as neutral with no significant recent trends.
Wall Street analysts forecast BLBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLBX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast BLBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLBX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
